my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
08-05-2012: Intercell AG announced the signing of a combined debt and equity financing with BB Biotech. The investment through a fully owned subsidiary of BB Biotech AG consists of a EUR 20.0 million secured loan (the “Term Loan”) and a commitment to invest EUR 5.0 million as part of a proposed equity private placement (the “Private Placement”).
Intercell is in discussions with specialized healthcare investors regarding proposals for additional investment of EUR 10.0 to 15.0 million as part of the Private Placement. The BB Biotech investment and the Private Placement, which should close before the end of May, are expected to secure Intercell’s funding needs into financial self‐sustainability.
Intercell’s CEO, Thomas Lingelbach, stated: “Following the successful strategic resetting in 2011, this financing marks an important step in the renewal of Intercell as a notable biotech vaccine company. With growing sales from our first product on the market, a diversified pipeline and technology base and a disciplined financial strategy, we are now very well positioned for the next development phase of our company.”
The EUR 20.0 million secured Term Loan provided by BB Biotech has a six‐year term. Repayment starts in the fourth year through twelve equal quarterly installments. The loan carries a variable interest rate of EURIBOR plus 6.5% (but not less than 10.9 %). In addition, Intercell will pay BB Biotech a royalty of 5.0% on its sales revenues from IXIARO®/JESPECT® (decreasing to 1.5% for sales revenues in excess of EUR 50.0 million) for a ten‐year period.
However, Intercell has certain buy‐out rights, which cap the overall interest, royalty and principal repayments. The loan is secured by a security interest in the assets related to IXIARO®/JESPECT®.
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
Intercell AG announced the results from a Phase I study investigating Intercell's adjuvant patch (Vaccine Enhancement Patch - VEP) containing LT (a heat-labile toxin from E. coli) in combination with an IM administration of an A/H5N1 antigen supplied by GSK.This trial follows earlier Phase ... more
Intercell completes equity private placement of EUR 15.2 million
Intercell AG announced that it successfully completed a previously announced financing transaction consisting of a EUR 20.0 million secured loan (the “Term Loan”) provided by BB Biotech and an equity private placement (the “Private Placement”) of approximately EUR 15.2 million. The Intercel ... more
Intercell announces EUR 25.0 million financing from BB Biotech
Intercell AG announced the signing of a combined debt and equity financing with BB Biotech. The investment through a fully owned subsidiary of BB Biotech AG consists of a EUR 20.0 million secured loan (the “Term Loan”) and a commitment to invest EUR 5.0 million as part of a proposed equity ... more
Intercell AG is a growing biotechnology company which focuses on the design and development of novel vaccines for prevention and treatment of infectious diseases with substantial unmet medical need. The Company develops antigens and immunizers (adjuvants) which are derived from its propriet ... more
Intercell announces EUR 25.0 million financing from BB Biotech
Intercell AG announced the signing of a combined debt and equity financing with BB Biotech. The investment through a fully owned subsidiary of BB Biotech AG consists of a EUR 20.0 million secured loan (the “Term Loan”) and a commitment to invest EUR 5.0 million as part of a proposed equity ... more
BB BIOTECH AG was founded in Switzerland in November 1993 as an investment company and invests in biotech companies globally. BB BIOTECH has meanwhile become one of the largest pure play biotech investors. BB BIOTECH shares are listed on the Swiss Stock Market, in the "TecDax" in Germany an ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
